Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Caitlin D LoweryMichele DowlessMatthew RenschlerWayne BlosserAlle B VanWyeJennifer R StephensPhilip W IversenAimee Bence LinRichard P BeckmannKateryna KrytskaKristina A ColeJohn M MarisDouglas S HawkinsBrian P RubinRaushan T KurmashevaPeter J HoughtonRichard G GorlickE Anders KolbMin H KangC Patrick ReynoldsStephen W EricksonBeverly A TeicherMalcolm A SmithLouis F StancatoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Prexasertib has significant antitumor effects as a monotherapy or in combination with chemotherapy in multiple preclinical models of pediatric cancer. These findings support further investigation of prexasertib in pediatric malignancies.